PubRank

Thierry Calandra

Author PubWeight™ 212.99‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008 31.57
2 Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004 24.47
3 Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008 20.88
4 Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2007 8.33
5 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002 7.81
6 Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008 5.39
7 Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004 4.56
8 Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004 3.25
9 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008 3.19
10 Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med 2011 2.77
11 Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 2010 2.69
12 Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008 2.55
13 IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 2013 2.24
14 Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 2009 2.24
15 Sepsis: time to reconsider the concept. Crit Care Med 2008 2.17
16 What's new in antimicrobial use and resistance in critically ill patients? Intensive Care Med 2013 2.11
17 Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis 2012 2.11
18 Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect 2002 2.10
19 Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur J Immunol 2005 2.09
20 Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc Natl Acad Sci U S A 2009 2.04
21 β-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Am J Respir Crit Care Med 2013 1.95
22 Impact of matrix-assisted laser desorption ionization time-of-flight mass spectrometry on the clinical management of patients with Gram-negative bacteremia: a prospective observational study. Clin Infect Dis 2012 1.83
23 Outcome measures for clinical research in sepsis: a report of the 2nd Cambridge Colloquium of the International Sepsis Forum. Crit Care Med 2005 1.77
24 The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity. Mol Endocrinol 2007 1.73
25 Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 2005 1.66
26 Antibiotic usage and resistance: gaining or losing ground on infections in critically ill patients? JAMA 2009 1.63
27 Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV. J Clin Oncol 2013 1.57
28 Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal 2005 1.53
29 Sepsis studies need new direction. Lancet Infect Dis 2012 1.50
30 Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care 2008 1.49
31 Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells. Endocr Relat Cancer 2013 1.49
32 Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS 2007 1.39
33 Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. J Biol Chem 2007 1.39
34 Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ 2003 1.37
35 Macrophage migration inhibitory factor: gene polymorphisms and susceptibility to inflammatory diseases. Clin Infect Dis 2005 1.36
36 Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Clin Infect Dis 2007 1.34
37 Bloodstream and endovascular infections due to Abiotrophia defectiva and Granulicatella species. BMC Infect Dis 2006 1.31
38 Critical role for Ets, AP-1 and GATA-like transcription factors in regulating mouse Toll-like receptor 4 (Tlr4) gene expression. Biochem J 2005 1.28
39 Innate immunogenetics: a tool for exploring new frontiers of host defence. Lancet Infect Dis 2007 1.22
40 Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. The EORTC International Antimicrobial Therapy Cooperative Group. N Engl J Med 1987 1.21
41 Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 2011 1.17
42 The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care 2010 1.17
43 Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review. Crit Care Med 2004 1.15
44 Macrophage migration inhibitory factor (MIF) regulates host responses to endotoxin through modulation of Toll-like receptor 4 (TLR4). J Endotoxin Res 2003 1.15
45 Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin. Antimicrob Agents Chemother 2010 1.11
46 A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS One 2011 1.10
47 Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob Agents Chemother 2006 1.09
48 A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal disease. FASEB J 2011 1.05
49 Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. Diagn Microbiol Infect Dis 2005 1.03
50 Resistance of Candida spp. to antifungal drugs in the ICU: where are we now? Intensive Care Med 2014 1.02
51 Identification and characterization of novel classes of macrophage migration inhibitory factor (MIF) inhibitors with distinct mechanisms of action. J Biol Chem 2010 1.01
52 Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients. Intensive Care Med 2009 1.00
53 Estradiol and progesterone strongly inhibit the innate immune response of mononuclear cells in newborns. Infect Immun 2011 1.00
54 Pancreatic stone protein as an early biomarker predicting mortality in a prospective cohort of patients with sepsis requiring ICU management. Crit Care 2012 1.00
55 Macrophage migration inhibitory factor deficiency is associated with impaired killing of gram-negative bacteria by macrophages and increased susceptibility to Klebsiella pneumoniae sepsis. J Infect Dis 2012 0.99
56 A new class of isothiocyanate-based irreversible inhibitors of macrophage migration inhibitory factor. Biochemistry 2009 0.98
57 Regulation of constitutive and microbial pathogen-induced human macrophage migration inhibitory factor (MIF) gene expression. Eur J Immunol 2007 0.98
58 Lack of Mycobacterium tuberculosis-specific interleukin-17A-producing CD4+ T cells in active disease. Eur J Immunol 2013 0.97
59 Histone deacetylase inhibitors impair antibacterial defenses of macrophages. J Infect Dis 2011 0.97
60 Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens. PLoS One 2012 0.96
61 MIF production by dendritic cells is differentially regulated by Toll-like receptors and increased during rheumatoid arthritis. Cytokine 2006 0.96
62 Infections in neutropenic cancer patients. Lancet 2002 0.95
63 Invasive mould infections: a multi-disciplinary update. Med Mycol 2009 0.95
64 Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C. PLoS One 2013 0.92
65 Invasive candidiasis: comparison of management choices by infectious disease and critical care specialists. Intensive Care Med 2005 0.90
66 Coxiella burnetii vascular graft infection. BMC Infect Dis 2005 0.90
67 Neutralization of macrophage migration inhibitory factor (MIF) by fully human antibodies correlates with their specificity for the β-sheet structure of MIF. J Biol Chem 2012 0.90
68 Treatment options of invasive fungal infections in adults. Swiss Med Wkly 2006 0.90
69 Macrophage migration inhibitory factor deficiency leads to age-dependent impairment of glucose homeostasis in mice. J Endocrinol 2010 0.89
70 A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group Study of secondary infections in febrile, neutropenic patients with cancer. Clin Infect Dis 2004 0.88
71 Macrophage migration inhibitory factor reduces the growth of virulent Mycobacterium tuberculosis in human macrophages. Infect Immun 2005 0.88
72 Histone deacetylase inhibitors repress macrophage migration inhibitory factor (MIF) expression by targeting MIF gene transcription through a local chromatin deacetylation. Biochim Biophys Acta 2009 0.87
73 Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C. PLoS One 2012 0.87
74 Changing face of health-care associated fungal infections. Curr Opin Infect Dis 2005 0.86
75 Liquid chromatography-mass spectrometry method for quantification of caspofungin in clinical plasma samples. J Mass Spectrom 2007 0.85
76 Glucocorticoid-induced MIF expression by human CEM T cells. Cytokine 2009 0.85
77 Monitoring procalcitonin in febrile neutropenia: what is its utility for initial diagnosis of infection and reassessment in persistent fever? PLoS One 2011 0.85
78 Invasive candidiasis in critically ill patients: does progressing knowledge improve clinical management and outcome? Curr Opin Crit Care 2010 0.84
79 Macrophage migration inhibitory factor (MIF) in meningococcal septic shock and experimental human endotoxemia. Shock 2007 0.83
80 Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. Crit Care Med 2009 0.83
81 Increased macrophage migration inhibitory factor (MIF) plasma levels in acute HIV-1 infection. Cytokine 2012 0.83
82 Polymorphisms in tumor necrosis factor-α increase susceptibility to intra-abdominal Candida infection in high-risk surgical ICU patients*. Crit Care Med 2014 0.82
83 The role of macrophage migration inhibitory factor in mouse islet transplantation. Transplantation 2008 0.82
84 Species-specific recognition of Aspergillus fumigatus by Toll-like receptor 1 and Toll-like receptor 6. J Infect Dis 2012 0.82
85 Antifungals in the ICU. Curr Opin Infect Dis 2008 0.81
86 Host innate immune responses to microbial pathogens. Curr Vasc Pharmacol 2013 0.81
87 Serum and BAL macrophage migration inhibitory factor levels in HIV infected Tanzanians with pulmonary tuberculosis or other lung diseases. Clin Immunol 2007 0.81
88 Modulation of human memory T-cell function by different antigen-presenting cells. Eur J Immunol 2011 0.81
89 Histoplasma capsulatum var. duboisii infection in a patient with AIDS: rapid diagnosis using polymerase chain reaction-sequencing. Diagn Microbiol Infect Dis 2009 0.81
90 Interleukin-33 safeguards neutrophils in sepsis. Nat Med 2010 0.79
91 Role of MyD88 and Toll-like receptors 2 and 4 in the sensing of Parachlamydia acanthamoebae. Infect Immun 2010 0.79
92 TLR2-mediated neutrophil depletion exacerbates bacterial sepsis. Proc Natl Acad Sci U S A 2009 0.79
93 Expression and function of macrophage migration inhibitory factor (MIF) in melioidosis. PLoS Negl Trop Dis 2010 0.79
94 Antifungal prophylaxis for intensive care unit patients: let's fine tune it. Intensive Care Med 2002 0.79
95 High imipenem blood concentrations associated with toxic encephalopathy in a patient with mild renal dysfunction. Int J Antimicrob Agents 2009 0.78
96 Imipenem underdosing as a cause of persistent neutropenic fever? J Antimicrob Chemother 2009 0.76
97 Exhaustion is associated with low macrophage migration inhibitory factor expression in patients with coronary artery disease. Psychosom Med 2007 0.76
98 A revival for immunoglobulin therapy in septic shock? Intensive Care Med 2014 0.75
99 Response to van Saene et al.'s comment on "Prevention of severe Candida infections in non-neutropenic, high-risk, critically ill patients". Intensive Care Med 2003 0.75
100 A new step toward individualized antifungal prevention in hematopoietic stem cell transplantation. Clin Infect Dis 2009 0.75
101 [New therapeutic strategies in severe sepsis and septic shock]. Rev Med Suisse Romande 2004 0.75
102 [Pyoderma gangrenosum: diagnostic and therapeutic challenge]. Rev Med Suisse 2008 0.75
103 Welcome address. J Chemother 2007 0.75
104 [Superbugs from elsewhere]. Rev Med Suisse 2011 0.75
105 Cytokines and Escherichia coli Sepsis. Ecosal Plus 2006 0.75
106 [Infectious diseases have again a good future!]. Rev Med Suisse 2008 0.75
107 [Not Available]. Rev Med Suisse 2016 0.75
108 [Outpatient antibiotic use in urgent care - a controversy]. Rev Med Suisse 2009 0.75
109 [Holy virus!]. Rev Med Suisse 2010 0.75
110 Candida arteritis in patients who have not received organ transplants: case report and review of the literature. Clin Infect Dis 2008 0.75